A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Lowest Effective Dose of Combinations of Drospirenone and 17 Beta-Estradiol for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women.
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Estradiol/drospirenone (Primary) ; Estradiol
- Indications Hot flashes
- Focus Therapeutic Use
- Sponsors Bayer
- 17 May 2011 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
- 25 Jan 2011 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
- 17 Dec 2009 Patient numbers amended from 910 to 735 as reported by ClinicalTrials.gov.